Cost-effectiveness analysis of combination therapies involving novel agents for first/second-relapse patients with multiple myeloma: a Markov model approach with calibration techniques

Table 5 The result of base-case analysis over lifetime horizon

Strategies	LYs	QALY	Incremental QALY	Costs, ¥	Incremental Costs, ¥	ICER, ¥/QALY	Rank by Cost-effectiveness
Bortezomib Group
Vd	4.01	2.42	Ref	783,775	Ref	Ref	2
PVd	4.22	2.56	0.14	795,833	12,058	86,129	1
SVd	4.79	2.80	0.38	1,202,452	418,677	1,101,782	3
DVd	5.33	3.15	0.73	1,584,081	800,306	1,096,310	4
Kd	5.05	2.94	0.52	1,666,528	882,753	1,697,602	5
PanVd	4.75	2.81	0.39	2,801,773	2,017,998	5,174,354	6
Lenalidomide Group
Rd	5.13	3.06	Ref	840,509	Ref	Ref	1
IxaRd	5.39	3.23	0.17	1,113,480	272,971	1,605,712	2
KRd	6.00	3.53	0.47	1,289,479	448,970	955,255	3
DRd	6.38	3.82	0.76	1,487,978	647,469	851,933	4
ERd	5.86	3.45	0.39	2,827,676	1,987,167	5,095,300	5
Carfilzomib Group
Kd	5.42	3.19	Ref	1,961,624	Ref	Ref	1
DKd	6.63	3.80	0.61	3,334,625	1,373,001	2,250,821	2
IsaKd	6.63	3.80	0.61	4,998,182	3,036,558	4,977,964	3

Vd bortezomib-dexamethasone, Rd lenalidomide-dexamethasone, Kd carfilzomib-dexamethasone, DVd daratumumab-bortezomib-dexamethasone, SVd selinexor-bortezomib-dexamethasone, PVd pomalidomide-bortezomib-dexamethasone, PanVd pomalidomide-bortezomib-dexamethasone, ERd elotuzumab-lenalidomide-dexamethasone, DRd daratumumab-lenalidomide-dexamethasone, KRd carfilzomib-lenalidomide-dexamethasone, IxaRd ixazomib-lenalidomide-dexamethasone, Kd carfilzomib-dexamethasone, DKd daratumumab-carfilzomib-dexamethasone, IsaKd isatuximab-carfilzomib-dexamethasone

ISSN: 2191-1991